Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5314 Target Snapshot

Tyrosine-protein kinase receptor TYRO3 · SINGLE PROTEIN · Homo sapiens

3,709Compounds
361Assays
9Approved Drugs
3,521.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q06418. Use UniProt Q06418 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q06418 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase receptor TYRO3 as ChEMBL target CHEMBL5314, mapped to UniProt Q06418. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase receptor TYRO3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5314
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q06418
Tyrosine-protein kinase receptor TYRO3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein kinase receptor TYRO3 is the right protein anchor across sources, using UniProt Q06418 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase receptor TYRO3
UniProt AccessionQ06418
Component TypeProtein
Sequence Length890 aa

Tyrosine-protein kinase receptor TYRO3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Tyrosine-protein kinase receptor TYRO3, mapped to UniProt Q06418. Sequence length is 890 aa.

Mapped IDQ06418
Review nameTyrosine-protein kinase receptor TYRO3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

9
Approved
7
Phase III
11
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC502,615.0
KI776.0
EC501.0
KD129.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5981096 11.0 IC50 0.01 Preclinical
CHEMBL5741930 10.92 IC50 0.012 Preclinical
CHEMBL5782595 10.92 IC50 0.012 Preclinical
CHEMBL5817527 10.92 IC50 0.012 Preclinical
CHEMBL5873205 10.92 IC50 0.012 Preclinical
CHEMBL5926926 10.39 IC50 0.041 Preclinical
CHEMBL6060115 10.39 IC50 0.041 Preclinical
CHEMBL5981781 10.28 IC50 0.052 Preclinical
CHEMBL5997590 10.22 IC50 0.06 Preclinical
CHEMBL5745182 10.01 IC50 0.097 Preclinical
Distribution

pChEMBL Value Distribution

100
5.0
228
5.5
485
6.0
414
6.5
366
7.0
86
7.5
139
8.0
28
8.5
12
9.0
18
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
BOSUTINIB
CHEMBL288441
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
VANDETANIB
CHEMBL24828
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

361
Total Assays
1,590
Tested Compounds
2
Assay Types
Binding — 358 assays, 1,590 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 292 1,558 6.6
assay format 40 12 6.8
cell-based format 26 20 5.8
Functional — 3 assays, 198 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 197 5.8
cell-based format 1 1 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine